Hainan Haiyao (000566) Fundamentals 2026 — Revenue Analysis | SniperIQ
Hainan Haiyao (000566) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥6.8B, trading at ¥5.21 on the SHZ. This SniperIQ fundamentals page covers Hainan Haiyao's valuation, profitability (net margin -55.3%), revenue (¥831M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hainan Haiyao's market cap?
Hainan Haiyao (000566) has a market capitalization of approximately ¥6.8B, trading at ¥5.21 on the SHZ. Market cap moves with the live share price.
What is Hainan Haiyao's P/E ratio?
Hainan Haiyao's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1520.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hainan Haiyao?
Hainan Haiyao runs a net profit margin of -55.3%, a gross margin of 23.4%, and an operating margin of -47.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hainan Haiyao generate?
Hainan Haiyao reported revenue of ¥831M for fiscal year 2025, with net income of -¥430M and earnings per share (EPS) of -0.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hainan Haiyao pay a dividend?
Hainan Haiyao does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Hainan Haiyao financially healthy?
Hainan Haiyao carries a debt-to-equity ratio of 585.82x and a current ratio of 0.34x, with a market beta of 0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hainan Haiyao a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hainan Haiyao (000566) the key facts are: market cap ¥6.8B, revenue ¥831M, 52-week range 3.56-9.24. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hainan Haiyao's full fundamentals live
Get Hainan Haiyao's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.